PerkinElmer Announces Financial Results for the Second Quarter of 2020

  • Revenue of $811.7 million; 12% reported growth; 13% organic growth
  • GAAP EPS from continuing operations of $1.23; Adjusted EPS of $1.57

WALTHAM, Mass.–(BUSINESS WIRE)–PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today reported financial results for the second quarter ended July 5, 2020.

The Company reported GAAP earnings per share from continuing operations of $1.23, as compared to GAAP earnings per share from continuing operations of $0.62 in the second quarter of 2019. GAAP revenue for the quarter was $811.7 million, as compared to $722.5 million in the second quarter of 2019. GAAP operating income from continuing operations for the quarter was $175.6 million, as compared to $91.7 million for the same period a year ago. GAAP operating profit margin was 21.6% as a percentage of revenue, as compared to 12.7% in the second quarter of 2019.

Adjusted earnings per share from continuing operations for the quarter was $1.57, as compared to $1.00 in the second quarter of 2019. Adjusted revenue for the quarter was $811.9 million, as compared to $722.7 million in the second quarter of 2019. Adjusted operating income from continuing operations for the quarter was $228.2 million, as compared to $146.0 million for the same period a year ago. Adjusted operating profit margin was 28.1% as a percentage of adjusted revenue, as compared to 20.2% in the second quarter of 2019.

Adjustments for the Company’s non-GAAP financial measures have been noted in the attached reconciliations.

“I could not be more proud of how we at PerkinElmer have met the obstacles that have faced us the past few months. We have proven to be a resilient, responsive, and agile organization,” said Prahlad Singh, president and chief executive officer of PerkinElmer. “Our strong second quarter results were truly a team effort and further reinforce the diversity of our business from a portfolio and geographic standpoint.”

Financial Overview by Reporting Segment for the Second Quarter

Discovery & Analytical Solutions

  • Second quarter 2020 revenue was $391.0 million, as compared to $434.0 million for the second quarter of 2019. Reported revenue decreased 10% and organic revenue decreased 10% as compared to the second quarter of 2019.
  • Second quarter 2020 operating income from continuing operations was $39.4 million, as compared to $57.7 million for the comparable prior period.
  • Second quarter 2020 adjusted operating income was $57.4 million, as compared to $81.5 million for the second quarter of 2019.

Diagnostics

  • Second quarter 2020 revenue was $420.7 million, as compared to $288.6 million for the second quarter of 2019. Reported revenue increased 46% and organic revenue increased 48% as compared to the second quarter of 2019.
  • Second quarter 2020 operating income from continuing operations was $160.3 million, as compared to $49.3 million for the comparable prior period.
  • Second quarter 2020 adjusted operating income was $189.6 million, as compared to $79.7 million for the second quarter of 2019.

Third Quarter 2020 Guidance

For the third quarter of 2020, the Company forecasts GAAP revenue in the range of $760 million to $860 million, GAAP earnings per share from continuing operations of $0.85 to $1.20 and, on a non-GAAP basis, which is expected to include the adjustments noted in the attached reconciliation, adjusted earnings per share of $1.18 to $1.53.

Conference Call Information

The Company will discuss its second quarter 2020 results and its outlook for business trends in a conference call on July 28, 2020 at 5:00 p.m. Eastern Time. To access the call, please dial (720) 405-2250 prior to the scheduled conference call time and provide the access code 4468217.

A live audio webcast of the call will be available on the Investors section of the Company’s Web site, www.perkinelmer.com. Please go to the site at least 15 minutes prior to the call in order to register, download, and install any necessary software. An archived version of the webcast will be posted on the Company’s Web site for a two-week period beginning approximately two hours after the call.

Use of Non-GAAP Financial Measures

In addition to financial measures prepared in accordance with generally accepted accounting principles (GAAP), this earnings announcement also contains non-GAAP financial measures. The reasons that we use these measures, a reconciliation of these measures to the most directly comparable GAAP measures, and other information relating to these measures are included below following our GAAP financial statements.

Factors Affecting Future Performance

This press release contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share, cash flow and revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities, acquisitions and divestitures. Words such as “believes,” “intends,” “anticipates,” “plans,” “expects,” “projects,” “forecasts,” “will” and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management’s current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These factors include, without limitation: (1) markets into which we sell our products declining or not growing as anticipated; (2) the effect of the COVID-19 pandemic on our sales and operations; (3) fluctuations in the global economic and political environments; (4) our failure to introduce new products in a timely manner; (5) our ability to execute acquisitions and license technologies, or to successfully integrate acquired businesses and licensed technologies into our existing business or to make them profitable, or successfully divest businesses; (6) our failure to adequately protect our intellectual property; (7) the loss of any of our licenses or licensed rights; (8) our ability to compete effectively; (9) fluctuation in our quarterly operating results and our ability to adjust our operations to address unexpected changes; (10) significant disruption in third-party package delivery and import/export services or significant increases in prices for those services; (11) disruptions in the supply of raw materials and supplies; (12) the manufacture and sale of products exposing us to product liability claims; (13) our failure to maintain compliance with applicable government regulations; (14) regulatory changes; (15) our failure to comply with healthcare industry regulations; (16) economic, political and other risks associated with foreign operations; (17) our ability to retain key personnel; (18) significant disruption in our information technology systems, or cybercrime; (19) our ability to obtain future financing; (20) restrictions in our credit agreements; (21) discontinuation or replacement of LIBOR; (22) the United Kingdom’s withdrawal from the European Union; (23) our ability to realize the full value of our intangible assets; (24) significant fluctuations in our stock price; (25) reduction or elimination of dividends on our common stock; and (26) other factors which we describe under the caption “Risk Factors” in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

About PerkinElmer

PerkinElmer, Inc. is a global leader focused on innovating for a healthier world. The Company reported revenue of approximately $2.9 billion in 2019, has about 13,000 employees serving customers in more than 190 countries, and is a component of the S&P 500 Index. Additional information is available through 1-877-PKI-NYSE, or at www.perkinelmer.com.

PerkinElmer, Inc. and Subsidiaries
CONDENSED CONSOLIDATED INCOME STATEMENTS
 

Three Months Ended

Six Months Ended

(In thousands, except per share data)

July 5, 2020

June 30, 2019

July 5, 2020

June 30, 2019

 
 
Revenue

$

811,718

 

$

722,517

 

$

1,464,114

 

$

1,371,254

 

 
Cost of revenue

 

364,374

 

 

374,724

 

 

708,747

 

 

715,655

 

Selling, general and administrative expenses

 

221,026

 

 

201,553

 

 

429,595

 

 

400,410

 

Research and development expenses

 

49,521

 

 

48,344

 

 

98,435

 

 

96,324

 

Restructuring and other, net

 

1,158

 

 

6,161

 

 

7,016

 

 

13,800

 

 
Operating income from continuing operations

 

175,639

 

 

91,735

 

 

220,321

 

 

145,065

 

 
Interest income

 

(192

)

 

(350

)

 

(457

)

 

(633

)

Interest expense

 

11,586

 

 

17,207

 

 

25,251

 

 

33,057

 

Loss on disposition of businesses and assets, net

 

 

 

336

 

 

 

 

2,469

 

Other (income) expense, net

 

(582

)

 

2,715

 

 

(3,989

)

 

1,580

 

 
Income from continuing operations, before income taxes

 

164,827

 

 

71,827

 

 

199,516

 

 

108,592

 

 
Provision for income taxes

 

27,614

 

 

2,686

 

 

28,588

 

 

3,998

 

 
Income from continuing operations

 

137,213

 

 

69,141

 

 

170,928

 

 

104,594

 

 
Loss on disposition of discontinued operations, before income taxes

 

 

 

 

 

 

 

 

Provision for income taxes on discontinued operations and dispositions

 

51

 

 

54

 

 

101

 

 

95

 

 
Loss from discontinued operations and dispositions

 

(51

)

 

(54

)

 

(101

)

 

(95

)

 
Net income

$

137,162

 

$

69,087

 

$

170,827

 

$

104,499

 

 
 
Diluted earnings per share:
Income from continuing operations

$

1.23

 

$

0.62

 

$

1.53

 

$

0.94

 

 
Loss from discontinued operations and dispositions

 

(0.00

)

 

(0.00

)

 

(0.00

)

 

(0.00

)

 
Net income

$

1.23

 

$

0.62

 

$

1.53

 

$

0.94

 

 
 
Weighted average diluted shares of common stock outstanding

 

111,869

 

 

111,528

 

 

111,756

 

 

111,411

 

 
ABOVE PREPARED IN ACCORDANCE WITH GAAP
 
Additional Supplemental Information (1):
(per share, continuing operations)
 
GAAP EPS from continuing operations

$

1.23

 

$

0.62

 

$

1.53

 

$

0.94

 

Amortization of intangible assets

 

0.42

 

 

0.37

 

 

0.84

 

 

0.72

 

Purchase accounting adjustments

 

0.01

 

 

0.05

 

 

(0.09

)

 

0.08

 

Acquisition and divestiture-related costs

 

(0.05

)

 

0.03

 

 

0.06

 

 

0.05

 

Significant litigation matters and settlements

 

0.03

 

 

0.00

 

 

0.03

 

 

0.01

 

Significant environmental matters

 

0.05

 

 

 

 

0.05

 

 

 

Disposition of businesses and assets, net

 

 

 

0.00

 

 

 

 

0.02

 

Restructuring and other, net

 

0.01

 

 

0.06

 

 

0.06

 

 

0.12

 

Tax on above items

 

(0.13

)

 

(0.13

)

 

(0.25

)

 

(0.25

)

Adjusted EPS

$

1.57

 

$

1.00

 

$

2.24

 

$

1.69

 

 
(1) amounts may not sum due to rounding

PerkinElmer, Inc. and Subsidiaries

REVENUE AND OPERATING INCOME (LOSS)

 

Three Months Ended

Six Months Ended

(In thousands, except percentages)

July 5, 2020

June 30, 2019

July 5, 2020

June 30, 2019

 
 
DAS Reported revenue $

391,002

 

$

433,967

 

$

789,397

 

$

822,800

 

 
Reported operating income from continued operations

39,430

 

57,689

 

67,943

 

94,616

 

OP%

10.1

%

13.3

%

8.6

%

11.5

%

Amortization of intangible assets

20,506

 

13,113

 

41,216

 

23,382

 

Purchase accounting adjustments

136

 

5,014

 

(11,334

)

5,051

 

Acquisition and divestiture-related costs

(5,486

)

416

 

6,833

 

959

 

Significant litigation matters and settlements

2,001

 

439

 

2,399

 

815

 

Restructuring and other, net

845

 

4,820

 

4,754

 

11,000

 

Adjusted operating income

57,432

 

81,491

 

111,811

 

135,823

 

Adjusted OP%

14.7

%

18.8

%

14.2

%

16.5

%

 
Diagnostics Reported revenue

420,716

 

288,550

 

674,717

 

548,454

 

Purchase accounting adjustments

196

 

192

 

392

 

384

 

Adjusted Revenue

420,912

 

288,742

 

675,109

 

548,838

 

 
Reported operating income from continued operations

160,300

 

49,255

 

189,891

 

80,741

 

OP%

38.1

%

17.1

%

28.1

%

14.7

%

Amortization of intangible assets

26,211

 

28,089

 

52,751

 

56,547

 

Purchase accounting adjustments

1,336

 

516

 

1,765

 

4,087

 

Acquisition and divestiture-related costs

263

 

478

 

305

 

1,485

 

Significant litigation matters and settlements

1,200

 

 

1,245

 

 

Restructuring and other, net

313

 

1,341

 

2,262

 

2,800

 

Adjusted operating income

189,623

 

79,679

 

248,219

 

145,660

 

Adjusted OP%

45.1

%

27.6

%

36.8

%

26.5

%

 
Corporate Reported operating loss

(24,091

)

(15,209

)

(37,513

)

(30,292

)

Significant environmental matters

5,242

 

 

5,242

 

 

Adjusted operating loss

(18,849

)

(15,209

)

(32,271

)

(30,292

)

 
Continuing Operations Reported revenue $

811,718

 

$

722,517

 

$

1,464,114

 

$

1,371,254

 

Purchase accounting adjustments

196

 

192

 

392

 

384

 

Adjusted Revenue

811,914

 

722,709

 

1,464,506

 

1,371,638

 

 
Reported operating income from continued operations

175,639

 

91,735

 

220,321

 

145,065

 

OP%

21.6

%

12.7

%

15.0

%

10.6

%

Amortization of intangible assets

46,717

 

41,202

 

93,967

 

79,929

 

Purchase accounting adjustments

1,472

 

5,530

 

(9,569

)

9,138

 

Acquisition and divestiture-related costs

(5,223

)

894

 

7,138

 

2,444

 

Significant litigation matters and settlements

3,201

 

439

 

3,644

 

815

 

Significant environmental matters

5,242

 

 

5,242

 

 

Restructuring and other, net

1,158

 

6,161

 

7,016

 

13,800

 

Adjusted operating income $

228,206

 

$

145,961

 

$

327,759

 

$

251,191

 

Adjusted OP%

28.1

%

20.2

%

22.4

%

18.3

%

 

REPORTED REVENUE AND REPORTED OPERATING INCOME (LOSS) PREPARED IN ACCORDANCE WITH GAAP

PerkinElmer, Inc. and Subsidiaries
CONDENSED CONSOLIDATED BALANCE SHEETS
 
 
(In thousands) July 5, 2020 December 29, 2019
 
Current assets:
Cash and cash equivalents

$

218,536

 

$

191,877

 

Accounts receivable, net

 

708,799

 

 

725,184

 

Inventories

 

477,707

 

 

356,937

 

Other current assets

 

122,541

 

 

100,381

 

Total current assets

 

1,527,583

 

 

1,374,379

 

 
Property, plant and equipment:
At cost

 

729,596

 

 

701,580

 

Accumulated depreciation

 

(406,807

)

 

(383,357

)

Property, plant and equipment, net

 

322,789

 

 

318,223

 

 
Operating lease right-of-use assets

 

195,222

 

 

167,276

 

Intangible assets, net

 

1,188,464

 

 

1,283,286

 

Goodwill

 

3,107,373

 

 

3,111,227

 

Other assets, net

 

291,555

 

 

284,173

 

Total assets

$

6,632,986

 

$

6,538,564

 

 
Current liabilities:
Current portion of long-term debt

$

9,762

 

$

9,974

 

Accounts payable

 

255,137

 

 

235,855

 

Short-term accrued restructuring and other

 

9,613

 

 

11,559

 

Accrued expenses and other current liabilities

 

550,067

 

 

503,332

 

Current liabilities of discontinued operations

 

2,097

 

 

2,112

 

Total current liabilities

 

826,676

 

 

762,832

 

 
Long-term debt

 

1,961,576

 

 

2,064,041

 

Long-term liabilities

 

703,208

 

 

751,468

 

Operating lease liabilities

 

177,893

 

 

146,399

 

Total liabilities

 

3,669,353

 

 

3,724,740

 

 
Total stockholders’ equity

 

2,963,633

 

 

2,813,824

 

Total liabilities and stockholders’ equity

$

6,632,986

 

$

6,538,564

 

 
PREPARED IN ACCORDANCE WITH GAAP
PerkinElmer, Inc. and Subsidiaries
CONSOLIDATED STATEMENTS OF CASH FLOWS
 
 
Three Months Ended Six Months Ended
July 5, 2020 June 30, 2019 July 5, 2020 June 30, 2019
(In thousands) (In thousands)
 
Operating activities:
Net income

$

137,162

 

$

69,087

 

$

170,827

 

$

104,499

 

Loss from discontinued operations and dispositions, net of income taxes

 

51

 

 

54

 

 

101

 

 

95

 

Income from continuing operations

 

137,213

 

 

69,141

 

 

170,928

 

 

104,594

 

Adjustments to reconcile income from continuing operations to net cash provided by (used in) continuing operations:
Stock-based compensation

 

9,604

 

 

6,703

 

 

12,654

 

 

12,801

 

Restructuring and other, net

 

1,158

 

 

6,161

 

 

7,016

 

 

13,800

 

Depreciation and amortization

 

59,289

 

 

53,324

 

 

120,047

 

 

103,793

 

Change in fair value of contingent consideration

 

879

 

 

59

 

 

(11,446

)

 

3,161

 

Amortization of deferred debt financing costs and accretion of discounts

 

935

 

 

929

 

 

1,642

 

 

1,790

 

Loss on disposition of businesses and assets, net

 

485

 

 

336

 

 

485

 

 

2,469

 

Amortization of acquired inventory revaluation

 

397

 

 

5,282

 

 

1,485

 

 

5,565

 

Changes in assets and liabilities which provided (used) cash, excluding effects from companies acquired:

 

 

Accounts receivable, net

 

(76,288

)

 

(17,468

)

 

4,312

 

 

(9,604

)

Inventories

 

(71,949

)

 

(12,009

)

 

(126,707

)

 

(50,450

)

Accounts payable

 

17,744

 

 

(38,500

)

 

20,907

 

 

(39,951

)

Accrued expenses and other

 

59,130

 

 

(27,100

)

 

(2,677

)

 

(106,425

)

Net cash provided by operating activities of continuing operations

 

138,597

 

 

46,858

 

 

198,646

 

 

41,543

 

Net cash used in operating activities of discontinued operations

 

 

 

 

 

 

 

 

Net cash provided by operating activities

 

138,597

 

 

46,858

 

 

198,646

 

 

41,543

 

 
Investing activities:
Capital expenditures

 

(16,650

)

 

(16,586

)

 

(37,138

)

 

(36,461

)

Purchases of investments

 

(5,755

)

 

 

 

(7,393

)

 

(868

)

Purchases of licenses

 

 

 

(348

)

 

 

 

(5,000

)

Proceeds from surrender of life insurance policies

 

79

 

 

 

 

131

 

 

 

Proceeds from disposition of businesses and assets

 

1,755

 

 

 

 

1,815

 

 

550

 

Payment of acquisitions, net of cash and cash equivalents acquired

 

(2,990

)

 

(240,354

)

 

(2,990

)

 

(244,738

)

Net cash used in investing activities of continuing operations

 

(23,561

)

 

(257,288

)

 

(45,575

)

 

(286,517

)

Net cash provided by investing activities of discontinued operations

 

 

 

 

 

 

 

 

Net cash used in investing activities

 

(23,561

)

 

(257,288

)

 

(45,575

)

 

(286,517

)

 
Financing Activities:
Payments on borrowings

 

(149,000

)

 

(426,000

)

 

(290,000

)

 

(578,000

)

Proceeds from borrowings

 

63,000

 

 

670,550

 

 

188,000

 

 

849,550

 

Payments of debt financing costs

 

 

 

(93

)

 

 

 

(181

)

Settlement of cash flow hedges

 

(3,671

)

 

16

 

 

5,037

 

 

(1,659

)

Net payments on other credit facilities

 

(1,753

)

 

(6,330

)

 

(6,036

)

 

(9,806

)

Payments for acquisition-related contingent consideration

 

(5,200

)

 

(11,600

)

 

(5,200

)

 

(23,700

)

Proceeds from issuance of common stock under stock plans

 

8,968

 

 

7,944

 

 

10,074

 

 

16,554

 

Purchases of common stock

 

(327

)

 

(764

)

 

(6,669

)

 

(6,057

)

Dividends paid

 

(7,791

)

 

(7,764

)

 

(15,572

)

 

(15,507

)

Net cash (used in) provided by financing activities of continuing operations

 

(95,774

)

 

225,959

 

 

(120,366

)

 

231,194

 

Net cash used in financing activities of discontinued operations

 

 

 

 

 

 

 

 

Net cash (used in) provided by financing activities

 

(95,774

)

 

225,959

 

 

(120,366

)

 

231,194

 

 
Effect of exchange rate changes on cash, cash equivalents, and restricted cash

 

5,510

 

 

235

 

 

(4,658

)

 

685

 

 
Net increase (decrease) in cash, cash equivalents, and restricted cash

 

24,772

 

 

15,764

 

 

28,047

 

 

(13,095

)

Cash, cash equivalents, and restricted cash at beginning of period

 

195,169

 

 

137,456

 

 

191,894

 

 

166,315

 

Cash, cash equivalents, and restricted cash at end of period

$

219,941

 

$

153,220

 

$

219,941

 

$

153,220

 

 
 
Supplemental disclosure of cash flow information:
Reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total shown in the consolidated statements of cash flows:
Cash and cash equivalents

$

218,536

 

$

150,016

 

$

218,536

 

$

150,016

 

Restricted cash included in other current assets

 

1,405

 

 

3,204

 

 

1,405

 

 

3,204

 

Total cash, cash equivalents and restricted cash

$

219,941

 

$

153,220

 

$

219,941

 

$

153,220

 

 
PREPARED IN ACCORDANCE WITH GAAP
PerkinElmer, Inc. and Subsidiaries
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES (1)
 
(In millions, except per share data and percentages)

PKI

Three Months Ended

July 5, 2020

June 30, 2019

 
Adjusted revenue:
Revenue

$

811.7

 

$

722.5

 

Purchase accounting adjustments

 

0.2

 

 

0.2

 

Adjusted revenue

$

811.9

 

$

722.7

 

 
Adjusted gross margin:
Gross margin

$

447.3

 

55.1

%

$

347.8

 

48.1

%

Amortization of intangible assets

 

16.0

 

2.0

%

 

15.6

 

2.2

%

Purchase accounting adjustments

 

0.6

 

0.1

%

 

5.5

 

0.8

%

Adjusted gross margin

$

463.9

 

57.1

%

$

368.9

 

51.0

%

 
Adjusted SG&A:
SG&A

$

221.0

 

27.2

%

$

201.6

 

27.9

%

Amortization of intangible assets

 

(30.7

)

-3.8

%

 

(25.6

)

-3.5

%

Purchase accounting adjustments

 

(0.9

)

-0.1

%

 

(0.1

)

0.0

%

Acquisition and divestiture-related expenses

 

5.2

 

0.6

%

 

(0.9

)

-0.1

%

Significant litigation matters and settlements

 

(3.2

)

-0.4

%

 

(0.4

)

-0.1

%

Significant environmental matters

 

(5.2

)

-0.6

%

 

 

0.0

%

Adjusted SG&A

$

186.2

 

22.9

%

$

174.6

 

24.2

%

 
R&D

$

49.5

 

6.1

%

$

48.3

 

6.7

%

 
Adjusted operating income:
Operating income

$

175.6

 

21.6

%

$

91.7

 

12.7

%

Amortization of intangible assets

 

46.7

 

5.8

%

 

41.2

 

5.7

%

Purchase accounting adjustments

 

1.5

 

0.2

%

 

5.5

 

0.8

%

Acquisition and divestiture-related expenses

 

(5.2

)

-0.6

%

 

0.9

 

0.1

%

Significant litigation matters and settlements

 

3.2

 

0.4

%

 

0.4

 

0.1

%

Significant environmental matters

 

5.2

 

0.6

%

 

 

0.0

%

Restructuring and other, net

 

1.2

 

0.1

%

 

6.2

 

0.9

%

Adjusted operating income

$

228.2

 

28.1

%

$

146.0

 

20.2

%

 

PKI

Three Months Ended

July 5, 2020

June 30, 2019

 
Adjusted EPS:
GAAP EPS

$

1.23

 

$

0.62

 

Discontinued operations, net of income taxes

 

(0.00

)

 

(0.00

)

GAAP EPS from continuing operations

 

1.23

 

 

0.62

 

Amortization of intangible assets

 

0.42

 

 

0.37

 

Purchase accounting adjustments

 

0.01

 

 

0.05

 

Acquisition and divestiture-related expenses

 

(0.05

)

 

0.03

 

Significant litigation matters and settlements

 

0.03

 

 

0.00

 

Significant environmental matters

 

0.05

 

 

 

Disposition of businesses and assets, net

 

 

 

0.00

 

Restructuring and other, net

 

0.01

 

 

0.06

 

Tax on above items

 

(0.13

)

 

(0.13

)

Adjusted EPS

$

1.57

 

$

1.00

 

 

DAS

Three Months Ended

July 5, 2020

June 30, 2019

 
Revenue

$

391.0

 

$

434.0

 

 
Adjusted operating income:
Operating income

$

39.4

 

10.1

%

$

57.7

 

13.3

%

Amortization of intangible assets

 

20.5

 

5.2

%

 

13.1

 

3.0

%

Purchase accounting adjustments

 

0.1

 

0.0

%

 

5.0

 

1.2

%

Acquisition and divestiture-related expenses

 

(5.5

)

-1.4

%

 

0.4

 

0.1

%

Significant litigation matters and settlements

 

2.0

 

0.5

%

 

0.4

 

0.1

%

Restructuring and other, net

 

0.8

 

0.2

%

 

4.8

 

1.1

%

Adjusted operating income

$

57.4

 

14.7

%

$

81.5

 

18.8

%

 

Diagnostics

Three Months Ended

July 5, 2020

June 30, 2019

 
Adjusted revenue:
Revenue

$

420.7

 

$

288.6

 

Purchase accounting adjustments

 

0.2

 

 

0.2

 

Adjusted revenue

$

420.9

 

$

288.7

 

 
Adjusted operating income:
Operating income

$

160.3

 

38.1

%

$

49.3

 

17.1

%

Amortization of intangible assets

 

26.2

 

6.2

%

 

28.1

 

9.7

%

Purchase accounting adjustments

 

1.3

 

0.3

%

 

0.5

 

0.2

%

Acquisition and divestiture-related expenses

 

0.3

 

0.1

%

 

0.5

 

0.2

%

Significant litigation matters and settlements

 

1.2

 

0.3

%

 

 

0.0

%

Restructuring and other, net

 

0.3

 

0.1

%

 

1.3

 

0.5

%

Adjusted operating income

$

189.6

 

45.1

%

$

79.7

 

27.6

%

 
(1) amounts may not sum due to rounding
PerkinElmer, Inc. and Subsidiaries
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES (1)
 
(In millions, except per share data and percentages)

PKI

Six Months Ended

July 5, 2020

June 30, 2019

 
Adjusted revenue:
Revenue

$

1,464.1

 

$

1,371.3

 

Purchase accounting adjustments

 

0.4

 

 

0.4

 

Adjusted revenue

$

1,464.5

 

$

1,371.6

 

 
Adjusted gross margin:
Gross margin

$

755.4

 

51.6

%

$

655.6

 

47.8

%

Amortization of intangible assets

 

32.1

 

2.2

%

 

30.4

 

2.2

%

Purchase accounting adjustments

 

1.9

 

0.1

%

 

6.0

 

0.4

%

Adjusted gross margin

$

789.3

 

53.9

%

$

692.0

 

50.5

%

 
Adjusted SG&A:
SG&A

$

429.6

 

29.3

%

$

400.4

 

29.2

%

Amortization of intangible assets

 

(61.9

)

-4.2

%

 

(49.5

)

-3.6

%

Purchase accounting adjustments

 

11.4

 

0.8

%

 

(3.2

)

-0.2

%

Acquisition and divestiture-related expenses

 

(7.1

)

-0.5

%

 

(2.4

)

-0.2

%

Acceleration of executive compensation

 

 

0.0

%

 

 

0.0

%

Significant litigation matters and settlements

 

(3.6

)

-0.2

%

 

(0.8

)

-0.1

%

Significant environmental matters

 

(5.2

)

-0.4

%

 

 

0.0

%

Adjusted SG&A

$

363.1

 

24.8

%

$

344.5

 

25.1

%

 
R&D

$

98.4

 

6.7

%

$

96.3

 

7.0

%

 
Adjusted operating income:
Operating income

$

220.3

 

15.0

%

$

145.1

 

10.6

%

Amortization of intangible assets

 

94.0

 

6.4

%

 

79.9

 

5.8

%

Purchase accounting adjustments

 

(9.6

)

-0.7

%

 

9.1

 

0.7

%

Acquisition and divestiture-related expenses

 

7.1

 

0.5

%

 

2.4

 

0.2

%

Acceleration of executive compensation

 

 

0.0

%

 

 

0.0

%

Significant litigation matters and settlements

 

3.6

 

0.2

%

 

0.8

 

0.1

%

Significant environmental matters

 

5.2

 

0.4

%

 

 

0.0

%

Restructuring and other, net

 

7.0

 

0.5

%

 

13.8

 

1.0

%

Adjusted operating income

$

327.8

 

22.4

%

$

251.2

 

18.3

%

 

PKI

Six Months Ended

July 5, 2020

June 30, 2019

 
Adjusted EPS:
GAAP EPS

$

1.53

 

$

0.94

 

Discontinued operations

 

(0.00

)

 

(0.00

)

GAAP EPS from continuing operations

 

1.53

 

 

0.94

 

Amortization of intangible assets

 

0.84

 

 

0.72

 

Purchase accounting adjustments

 

(0.09

)

 

0.08

 

Significant litigation matters and settlements

 

0.03

 

 

0.01

 

Significant environmental matters

 

0.05

 

 

 

Acquisition and divestiture-related expenses

 

0.06

 

 

0.05

 

Loss (gain) on disposition of businesses and assets, net

 

 

 

0.02

 

Restructuring and other, net

 

0.06

 

 

0.12

 

Tax on above items

 

(0.25

)

 

(0.25

)

Adjusted EPS

$

2.24

 

$

1.69

 

 

PKI

Three Months Ended
October 4, 2020
Adjusted EPS: Projected
GAAP EPS from continuing operations

$0.85 – $1.20

Amortization of intangible assets

 

0.43

 

Purchase accounting adjustments

 

0.01

 

Acquisition and divestiture-related expenses

 

0.00

 

Tax on above items

 

(0.11

)

Adjusted EPS

$1.18 – $1.53

 

DAS

Six Months Ended

July 5, 2020

June 30, 2019

 
Revenue

$

789.4

 

$

822.8

 

 
Adjusted operating income:
Operating income

$

67.9

 

8.6

%

$

94.6

 

11.5

%

Amortization of intangible assets

 

41.2

 

5.2

%

 

23.4

 

2.8

%

Purchase accounting adjustments

 

(11.3

)

-1.4

%

 

5.1

 

0.6

%

Acquisition and divestiture-related expenses

 

6.8

 

0.9

%

 

1.0

 

0.1

%

Significant litigation matters and settlements

 

2.4

 

0.3

%

 

0.8

 

0.1

%

Restructuring and other, net

 

4.8

 

0.6

%

 

11.0

 

1.3

%

Adjusted operating income

$

111.8

 

14.2

%

$

135.8

 

16.5

%

 

Diagnostics

Six Months Ended

July 5, 2020

June 30, 2019

 
Adjusted revenue:
Revenue

$

674.7

 

$

548.5

 

Purchase accounting adjustments

 

0.4

 

 

0.4

 

Adjusted revenue

$

675.1

 

$

548.8

 

 
Adjusted operating income:
Operating income

$

189.9

 

28.1

%

$

80.7

 

14.7

%

Amortization of intangible assets

 

52.8

 

7.8

%

 

56.5

 

10.3

%

Purchase accounting adjustments

 

1.8

 

0.3

%

 

4.1

 

0.7

%

Acquisition and divestiture-related expenses

 

0.3

 

0.0

%

 

1.5

 

0.3

%

Significant litigation matters and settlements

 

1.2

 

0.2

%

 

 

0.0

%

Restructuring and other, net

 

2.3

 

0.3

%

 

2.8

 

0.5

%

Adjusted operating income

$

248.2

 

36.8

%

$

145.7

 

26.5

%

 
(1) amounts may not sum due to rounding

Contacts

Investor Relations:

PerkinElmer, Inc.

Bryan Kipp (781) 663-5583

bryan.kipp@perkinelmer.com

Media Contact:

PerkinElmer, Inc.

Fara Goldberg (781) 663-5699

fara.goldberg@perkinelmer.com

Read full story here

error: Content is protected !!